For example, the presence of CD8+ and CD4+ T cells could improve clinical outcomes and prolong survival in different cancers [51–54], while T cell regulation (Tregs) may inhibit antitumor immune response and support the establishment of immune hyporesponse microenvironments in some tumor types [55]. The gene discussed is CD8A; the disease is cancer.